Brief: Advance Zinctek Says FDA Identifies GMP Compliance Issues Requiring Remediation
Nov 17 (Reuters) - Advance ZincTek ANO.AX: FDA INSPECTION UPDATE FDA IDENTIFIES GMP COMPLIANCE ISSUES REQUIRING REMEDIATION CURRENTLY NO IMPACT ON SUPPLY TO OUR U.S. CUSTOMERS FDA ALSO CONFIRMED THAT MATTERS RAISED IN ITS APRIL 2024 LETTER HAVE BEEN SATISFACTORILY CLOSED Further company coverage: ANO.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Advance Zinctek
See all newsBrief: Advance Zinctek Confirms Capital Return Of A$0.02 Per Share
Brief: Advance Zinctek Responds To TV Broadcast On Allegations Concerning Zinc Oxide Supplied By ANO In 2024
Brief: Advance Zinctek Says FDA Identifies GMP Compliance Issues Requiring Remediation
Brief: Advance Zinctek Confirms Zinc Oxide Not Used In Choice-Tested Sunscreens
Brief: Advance Zinctek Does Not Expect Negative Impact On U.S. Business